Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG13909 trial in congenital adrenal hyperplasia
2023-503711-15-00Phase 2Authorised
- Sponsor
- Lundbeck
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2 trial of Lu AG13909 in congenital adrenal hyperplasia (CAH), sponsored by Lundbeck. Planned start Jan 2024; status: authorised.
02
Drugs
Lu AG13909
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on 2023-503711-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503711-15-00.